Clinical Trial Update: Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the safety, tolerability, and preliminary efficacy of XH001 injection in combination with a neoantigen vaccine–induced tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• Neoantigen vaccine-induced tumor-specific T-cell injection
• XH001 (XH001)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Gastrointestinal Cancer | Phase 1 | Status: RECRUITING